Coronavirus | Opeds and editorials

In vaccine race last lap, the key steps for India

Evaluation of candidate vaccines for COVID-19 should be done on technical parameters and programmatic suitability. An ideal vaccine would provide all of these — immunity that is of a high degree (90% + protective especially against severe illness), broad scale (against different variants) and durable (at least five years if not lifelong); a vaccine that is safe (little or no side-effects and definitely no serious adverse effects); a vaccine that is cheap (similar to current childhood vaccines); a vaccine that is programmatically suitable (single dose, can be kept at room temperature or at worst needs simple refrigeration between 2°C and 4°C, needle-free delivery, and a vaccine that is available in multidose vials, has long shelf life and is amenable to rapid production.

Obviously, a vaccine having all these desirable characteristics is a pipe dream and most vaccines would fare well in some and not so well in other parameters, making it difficult to choose between them. Also, at this stage, we are only looking at a one-time use of this vaccine to stop the novel coronavirus pandemic as the requirement for a regular vaccination (as for influenza) would be somewhat different.

The Hindu Explains | Who are the top contenders in the race for a COVID-19 vaccine?

A difficult vaccine to develop

Historically, we have faced difficulties in the development of coronavirus vaccines. Although there were some attempts at development of vaccines against Severe Acute Respiratory Syndrome (SARS) and the Middle East Respiratory Syndrome (MERS), there are no licensed vaccines for any coronavirus yet. Previous coronavirus vaccines were found to be immunogenic (generate antibodies as in phase II) but did not effectively prevent acquisition of disease (phase III) fuelling a concern that vaccination may not induce long-lived immunity, and re-infection may be possible. There are also safety concerns due to immunological consequences of the vaccine as these vaccines use newer techniques with which we do not have long term or large population experience.

At this stage, it is not possible to comment much on the duration and breadth of protection of COVID-19 vaccine candidates. About the safety of vaccines, there are always possibilities of rare (one in million) or delayed (by months or years) serious adverse events which will come to light only after mass vaccination has started; this requires a good post-licensure surveillance system to be in place. We should be prepared for such eventualities, and a clear policy on their compensation should be framed.

Most could be in two doses

The COVID-19 vaccine candidates by Moderna and Pfizer have already released early information of high effectiveness (90%+). Pfizer’s two-dose shots need to be stored at minus 70°C) something which is beyond India’s current vaccine storage infrastructure. Moderna’s vaccine is more thermostable and has a requirement similar to what we used for oral polio vaccines. AstraZeneca, also a frontrunner, makes use of simplified storage settings as do many other candidates. As results of phase 3 trials of other vaccines are out, we will be faced with a dilemma of choice (referred to earlier). Almost all of them seem to require two doses.

Comment | The storage tale of two vaccines

Given this complicated scenario, what should the government strategy be while choosing a vaccine and for vaccination?

Ranking by risk category

The first rule would be to not to put all your eggs in one basket. We already know that government has planned for vaccine supply from different sources. The second rule would be to prioritise. The World Health Organization has issued guidelines for prioritisation for vaccine recipients. For this, we need to rank population sub-groups by risk category (risk of infection or adverse outcome or economic impact), and by programmatic ease of vaccination — based on their captivity (health-care workers, organised sector, workplace, schools), and access to existing channels of vaccination (pregnant women and children). Start with where these two criteria intersect — health-care workers followed by policemen. The third rule is use multiple channels to immunise the population. Other important considerations would be of equity and cost. Obviously, military and paramilitary staff will be dealt with as a special case due to their high captivity and national security considerations.

Coronavirus | Serum Institute of India stocking emergency doses of COVID-19 vaccine

The first product off the block may not be suitable in terms of cost and cold storage, but if the priority is health-care workers, then we could go ahead and buy some (how much is a trade- off) vaccines for this group if it is above 75% effective, as it is possible to immunise health-care workers keeping cold storage requirements at their own facility, including in private sector or district hospitals. The same infrastructure can also be used to vaccinate the police force. This will buy us some time to evaluate other vaccines and delivery options. The workplace and school-based vaccination roll-out could be the second phase of vaccination.

Models of social mobilisation

Problems will arise as we move towards vaccinating the general population, even high-risk groups (the elderly and those with co-morbidity) in the general population. It might be easier to vaccinate the institutionalised elderly as compared to community-dwelling ones. The only orderly option is to create some sort of a technological solution of a queuing system based on an earlier registration process for age and presence of co-morbidity and allotment of appointment in a nearest booth. It is essential that we avoid overcrowding during vaccination.

Interview | ‘Initial support will cover 92 low- and middle-income economies for COVID-19 vaccines’, says Gavi the Vaccine Alliance CEO Seth Berkley

However, the greatest challenge would be to immunise the poorest and the most vulnerable (slums/migrants/refugees/people with disabilities). Because of access issues, this must be by an outreach or camp approach (booths along with web-enabled appointments facilitated by civil society); a programmatically suitable vaccine will have to be prioritised for them. We have learnt major lessons through social mobilisation efforts during the Pulse Polio campaigns, Aadhaar card enrolment and elections, which will serve as good models. We have the wherewithal to do it. However, our Aadhaar experience shows that this will take time. Fortunately, for the pandemic to end, we need not have to immunise everybody. It is expected that the pandemic would start receding once we protect about 60% of the population (in terms of coverage x effectiveness). However, we should ensure that this coverage is well-spread out, else focal outbreaks will keep occurring in areas with poor vaccine coverage. This also raises the possibility of using a ring immunisation strategy (immunising the population around reported cases), even earlier.

Comment | More than a vaccine, it is about vaccination

Dealing with ‘pay and get’

One major challenge would be that many people would be willing to pay for the vaccine and ask for expedited access. So, should we allow this? Obviously, till we cover a bulk of phase 1 beneficiaries, the government should not concern itself with other groups. However, it can and should allow the vaccine to be available in the private sector at a market-driven price for such people. It will be ethical as well as cost-saving for the government, if it does not divert vaccines from the government-driven programme. Let the decision to wait for a government-delivered vaccine or one from the private sector be made by individuals, and not the government. It will also free the government to focus more on “needy” people.

Many countries have already published their prioritisation policy whereas in India, it is only based on what we hear from the media — that health-care workers have been prioritised and details are not available in the public domain. It is critical that the government has a fair, transparent and published policy in this regard even if it results in heartburn in some quarters. Choosing, paying for vaccines and their administration by governments are going to be most challenging with no easy answers. And I expect some missteps early in the game. I would not like to be in those shoes, as public criticism is inevitable.

Watch | What are vaccines?
 

Dr. Anand Krishnan is Professor at the Centre for Community Medicine, All India Institute of Medical Sciences, New Delhi. The views expressed are personal

Related Topics
This article is closed for comments.
Please Email the Editor

Printable version | Jan 21, 2021 2:26:12 AM | https://www.thehindu.com/opinion/lead/in-vaccine-race-last-lap-the-key-steps-for-india/article33156159.ece

In This Package
Managing the rollout: On addressing vaccine hesitancy
Injecting confidence: On India’s COVID-19 vaccination drive
Vaccine optimism and the scientific uncertainty link
Building trust in vaccines
The debilitating side-effect of a flawed vaccine trial
Gearing up: On vaccines and public trust
A hurried gamble: On vaccines and transparency
The second dose: On COVID-19 vaccine
A constant vigil: On the new coronavirus strain in India
Unmasked, reflections on the pandemic and life
Caution pays: On Centre’s COVID-19 surveillance guidelines
Towards an effective vaccination distribution policy
Essential dry run: On COVID-19 vaccination drive
COVID-19 and limits of political accountability
The purpose of a vaccine
Clear the fog, draw up a clear vaccination policy
Rein in the vaccine nationalism, the profiteering
You are reading
In vaccine race last lap, the key steps for India
The storage tale of two vaccines
T-cell immunity and COVID-19
COVID-19, climate and carbon neutrality
Signs of easing: On India’s COVID-19 fight
Has India passed the COVID-19 peak?
Sooner, better: On indigenously developed COVID-19 test kits
The battered Puja economy
Outline of a pandemic fight, by and for citizens
Pandemics and the collective consciousness
Vaccines with a global common good guarantee
Saving lives under the long shadow of the pandemic
Until vaccine: On Unlock 5
The challenge of changing health behaviour
Weighing the costs: On COVID-19 vaccine
The slow and frustrating journey of recovering from COVID-19
Health worker safety deserves a second look
Unlocking campuses: On UGC’s revised academic calendar
Recovery from COVID-19 can be a struggle
Uniting to combat COVID-19
Coronavirus fears and preconception advice
An agriculture-led revival as flawed claim
A necessary pause: On the COVID-19 vaccine race
The uncertainties over COVID-19 numbers
The challenges in counting the dead
COVID-19 deaths may be higher than reported
The many challenges in estimating deaths
Alone at the top: On India’s COVID-19 numbers
The participants we need in Phase 3 trials
Differential impact of COVID-19 and the lockdown
More than a vaccine, it is about vaccination
COVID-19 and a country club India must leave
A quest for order amid cyber insecurity
Adopting a public systems approach to COVID-19
Milestone of a million: On India’s COVID-19 numbers
Testing times: On university exams
Predictions, pandemics and public health
It’s time to flatten the pandemic stereotyping
Viral outrage only spikes the data
Sending the right message
Needed: Clear testing data
The social contract needs to be rewritten
The pandemic is about eyes shut
Joblessness and opportunity in Tamil Nadu
Green-lighting ecological decimation amidst a pandemic
COVID-19 has no religion
A case for extension: On rural jobs scheme
Surely, even if slowly: On a COVID-19 vaccine
Bend it like Italy: On flattening the COVID-19 curve
Promise and delivery: On India’s first COVID-19 vaccine
States hold the key: On Unlock 2.0
PCR testing is a double-edged sword
Science vs nonsense: On Patanjali’s COVID-19 claim
Shut and open: On tennis during the pandemic
The perils of follow the leader syndrome
The many questions about Favipiravir
In new lockdown, a second chance for Tamil Nadu
United front in Delhi: On Kejriwal government-Centre camaraderie
A prescription of equitable and effective care
Multilateralism post COVID-19
Making public transport safe during COVID-19
A better rate: On COVID-19 recovery
Look back in relief: On the migrant labour crisis
Needed, a transfusion for public health care
Wrong priorities: On keeping religious places open during a pandemic
Crossing the line: On Delhi’s decision to limit health services
Profit, not profiteering: On regulation of COVID-19 testing charges
In Persian Gulf littoral, cooperative security is key
Paging the private sector in the COVID fight
Curves and recoveries: On India’s coronavirus numbers
India’s Parliament is missing in action
Axing the economy’s trunk
Scripting a new narrative for COVID control
Open with caution: On Unlock 1
It’s time for a universal basic income programme in India
The waning of subaltern solidarity for Hindutva
Export blocks: On India’s trade amid the pandemic
A moment to trust the teacher
The echo of migrant footfalls and the silence on policy
Enjoying the fruits of their labour
Helping supply chains recover
The heavy burden of social suffering
An effective lockdown
The lockdown has highlighted stark inequalities
Will sport be the same in empty stadia?
Cinema after COVID-19
The eternal longing for the distant home
Working safely: On workplaces during the pandemic
A hole in the whole: On health sector woes
China, better prepared for the post-COVID world
How public health boosts an economy
Keep it retrospective
Backing the ‘angels in white coats’
Standstill: On opening of stadia for training
Flawed stimulus is justice denied
We need social physicians
A callous response
Peaking: On India’s coronavirus tally
Farm gate in focus: On amending Essential Commodities Act
A question of quarantine: On migrant workers and other travellers
TASMAC tribulations: On Tamil Nadu liquor sale
The pandemic and the challenge of behaviour change
One for the poor: On Centre’s corona package
Lockdown syndrome: On virus-induced economic crisis
Are India’s labour laws too restrictive?
Stop the return to laissez-faire
States cannot be left to the Centre’s mercy
Local motif: On Modi’s call for self-reliance
Liquidity lifeline: On Nirmala’s MSME package
A plan to revive a broken economy
Provide income support, restore jobs
Perilous state: On State finances
COVID-19 and the path ahead
Reaffirm cooperative federalism
Riding roughshod over State governments
Tragedy on the tracks: On the killing of 16 migrant workers
Coming to terms: On India refusing to admit community transmission
The trends shaping the post-COVID-19 world
The epidemic and ensuring safety in courts
Responding to COVID-19 at the grassroots
The face of exploitation
Contempt for labour: On dilution of labour laws
Slower growth and a tighter fiscal
Back home: On return of Indian expatriates
Blame game: On Donald Trump’s anti-China rhetoric over COVID-19
Resuscitating multilateralism with India’s help
A war-like state and a bond to the rescue
Fear and loathing in the land of the free
Everyone wants a good stimulus
Rent control amidst pandemic
Slow release: On lockdown 3.0
No comfort in numbers: On Bengal’s coronavirus cases
Pandemics without borders, South Asia’s evolution
India’s disease surveillance system needs a reboot
No relief for the nowhere people
BRICS against COVID-19
Recovering early: On India’s COVID-19 patients
It’s about food, nutrition and livelihood security
Taiwan’s coronavirus protocol shows how it is done
Needed: a pandemic patent pool
Getty Images/iStockphoto
Plasma therapy is no silver bullet
Take care of yourself too, fellow journalists
Strategic shift: On home isolation of mild coronavirus cases
Coping with today, planning for tomorrow
No end in sight: On India’s coronavirus strategy
Vividly imagining the life of migrant workers
A task for South Asia
Privacy concerns during a pandemic
Unlocking justice in the lockdown
Safe return: On migrant worker distress
The outline of another pandemic combat strategy
Pandemic and panic: On Tamil Nadu’s five-city lockdown
Protecting the poor from becoming poorer
Did SARS-CoV-2 begin from a lab?
Protection for protectors: On safety of healthcare workers
Rapid failures: On antibody testing kits
The COVID-19 paradox in South Asia
Fishing in troubled waters during a pandemic
How will India emerge out of the lockdown?
Making doctors wash hands
Locked out of cities, homes and livelihoods
Script of unity: On coronavirus and social prejudices
Exploiting a pandemic: On Trump’s immigration policy
The village is still relevant
A time for planetary solidarity
There may be no going back
No transparency in West Bengal
Focus on the curve: On India’s COVID-19 numbers
Economy in lockdown: On India’s worst case scenario
A shot of hope with a game changing vaccine
Caught in the heightened arc of communal polemics
Singing the corona tune
Helping a lending hand: On RBI’s second lockdown stimulus
A season of change: On IMD forecast system
A virus, social democracy, and dividends for Kerala
Across the gulf: On stranded Indian workers
Virtual reality: On telemedicine
A blueprint to revive the economy
A case to use JEE-Main instead of JEE-Advanced this year
Will the aviation industry recover from the pandemic?
Data-driven reporting during COVID-19
Stress test: On revised lockdown guidelines
Disastrous decision: On Trump halting funds to WHO
Cease the distractions, seize the moment
Getting the containment strategy in India right
In India’s response, a communications failure
Harmonising with nature
End the harassment of farmers now
A narrowing window: On extension of lockdown
Corona bond: On Eurozone COVID-19 rescue package
Halting the march of rumours
Polls during a pandemic
The pandemic and the contours of a health response
Economic liberalisation and its faults
Invasive, alien, most fearsome
Trade in tatters: On the global slump
Wanted, a collective national endeavour
Disingenuous and no antidote
COVID-19 and the crumbling world order
Women’s safety during lockdown
Lives and livelihoods: On economy after lockdown
Stage fright: On denying community transmission
Team India and winning the pandemic battle
In time of need: On hydroxychloroquine export
Will COVID-19 affect the course of globalisation?
Finding a scapegoat in WHO
Curating news for children during pandemic
A time for extraordinary action
For better use: On MPLADS funds
Needed, greater decentralisation of power
A key arsenal in rural India’s pandemic fight
Preparing for exit: On lifting the lockdown
Sanctions and pandemic: On America’s Iran policy
‘A script of action, responsibility and compassion’: Chief Minister Ashok Gehlot writes on Rajasthan’s fight against COVID-19
Taking a long view of the pandemic fight
Ten questions posed by the virus
A different economic approach
Why healthcare workers above 60 should be ‘benched’
Enemy at the gates: On Kerala-Karnataka border row
Reducing farm distress during a pandemic
Why everyone should wear masks
The criticality of community engagement
A niggardliness that is economically unwarranted
The spectre of a post-COVID-19 world
Light and sound: On Narendra Modi’s 9-minute light ceremony
A million and counting: On global coronavirus spread
Safe forests, safe people: On diseases of animal origin
Quarantine and the law
Making the private sector care for public health
Looking east to contain COVID-19
Limits to rugged individualism
Uncritical endorsement: On exodus of migrant workers and the Supreme Court
Beyond the blame game: On the Tablighi Jamaat episode
A long road: On India’s 21-day coronavirus lockdown
The missing notes: On politics and the fight against COVID-19
China’s zero: On China’s lead in containing coronavirus
Unprecedented step: On Wuhan lockdown
The return of the expert
Lessons from Hubei
A pandemic in an unequal India
Faith can’t override public health
Devising a people-centric response to COVID-19
Karnataka CM writes on how the State is fighting the pandemic
Tamil Nadu CM writes on how the State is stopping the pandemic in its tracks
The hunt for a cure begins with telling the truth
COVID-19 and a city’s anatomy
Long live the nation-state
The COVID cycle
Coronavirus | The worst of times, the best of times
It’s also a fight against punitive measures
The age of the neoliberal virus
The deep void in global leadership
Thinking national, acting local
Every man is a part of the main
Beyond social distancing to fight COVID-19
Next Story